Pharmacoeconomic assessment of dual bronchodilation therapy in patients with COPD

Abstract

This study was aimed at clinical and economic assessment of feasibility of inclusion glycopyrronium bromide/indacaterol fixed combination in the State Program for providing necessary drugs to patients. Methods. This retrospective study was based on previously published clinical data. Change of economic burden was assessed using budget impact analysis. Cost-effectiveness was assessed using cost minimization analysis and lost opportunities analysis. Results. Switching COPD patients from free combination of long-acting bronchodilators (LABD) to glycopyrronium bromide/indacaterol fixed combination has led to 20.44% decrease in the economic burden. The 3-year cost saving of COPD therapy has reached RUB 2,416 bln. Conclusion. The results demonstrate pharmacoeconomic efficiency of glycopyrronium bromide/indacaterol fixed combination compared to the standard therapy of COPD. Inclusion of glycopyrronium bromide/indacaterol combination into the State Program for providing necessary drugs to COPD patients could be rational and ecomonically feasible.